News
Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.
Futurism on MSN6h
Human Experiments on GLP-1 Pill Looking Extremely PromisingA new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.
One of those is Boston-based Syntis Bio, which is working on a daily pill that mimics the effects of gastric bypass—no actual ...
Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback